Showing metabocard for Latanoprost (HMDB0014792)
`
`Show more...
`
`Show Metabolites with Similar Structures
`
`

`

`Human Metabolome Database: Showing metabocard for Latanoprost (HMDB0014792)
`
`Page 2 of 5
`
`Substituents
`
`• Prostaglandin skeleton
`• Fatty acid ester
`• Monocyclic benzene moiety
`• Cyclopentanol
`• Benzenoid
`• Cyclic alcohol
`• Carboxylic acid ester
`• Secondary alcohol
`• Carboxylic acid derivative
`• Monocarboxylic acid or derivatives
`• Hydrocarbon derivative
`• Organic oxide
`• Alcohol
`• Carbonyl group
`• Organic oxygen compound
`• Organooxygen compound
`• Aromatic homomonocyclic compound
`
`Molecular Framework
`
`Aromatic homomonocyclic compounds
`
`External Descriptors
`
`Ontology
`
`Disposition
`
`(http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6384))
`• carboxylic ester (CHEBI:6384
`
`• prostaglandins Falpha (CHEBI:6384
`(http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6384))
`
`• triol (CHEBI:6384
`(http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:6384))
`
`
`Route of exposure:
`
`Enteral:
`
`◦ Ingestion (/metabolite_ontology_terms/4903893)
`
`Source:
`
`◦ Food (/metabolite_ontology_terms/4903892)
`
`Biological location:
`
`Biofluid and excreta:
`
`◦ Urine (/metabolite_ontology_terms/3407383)
`
`◦ Blood (/metabolite_ontology_terms/3407384)
`
`Cell and elements:
`
`◦ Extracellular (/metabolite_ontology_terms/3240349)
`
`Subcellular:
`
`◦ Membrane (/metabolite_ontology_terms/3240350)
`
`◦ Cell membrane (/metabolite_ontology_terms/3674477)
`
`◦ Cytoplasm (/metabolite_ontology_terms/3835947)
`
`Process
`
`Naturally occurring process:
`
`Biological process:
`
`Biochemical process:
`
`◦ Lipid transport (/metabolite_ontology_terms/4903896)
`
`◦ Lipid metabolism (/metabolite_ontology_terms/4903897)
`
`◦ Fatty acid metabolism (/metabolite_ontology_terms/4903898)
`
`Chemical reaction:
`
`◦ Lipid peroxidation (/metabolite_ontology_terms/4903895)
`
`Biochemical pathway:
`
`◦ Lipid metabolism pathway (/metabolite_ontology_terms/4903894)
`
`Multicellular process:
`
`◦ Inflammatory response (/metabolite_ontology_terms/3835951)
`
`◦ Immune response (/metabolite_ontology_terms/3835952)
`
`Cellular process:
`
`◦ Cell signaling (/metabolite_ontology_terms/3449682)
`
`Role
`
`Biological role:
`
`◦ Membrane stabilizer (/metabolite_ontology_terms/3674474)
`
`◦ Energy source (/metabolite_ontology_terms/3674475)
`
`◦ Energy storage (/metabolite_ontology_terms/3674476)
`
`◦ Nutrient (/metabolite_ontology_terms/3835948)
`
`◦ Inflammatory (/metabolite_ontology_terms/3835949)
`
`Modulator:
`
`◦ Immunomodulator (/metabolite_ontology_terms/3835950)
`
`Industrial application:
`
`◦ Drug (/metabolite_ontology_terms/3449680)
`
`◦ Surfactant (/metabolite_ontology_terms/3674472)
`
`◦ Emulsifier (/metabolite_ontology_terms/3674473)
`
`Pharmaceutical industry:
`
`◦ Pharmaceutical (/metabolite_ontology_terms/3602520)
`
`Cardiovascular drug:
`
`◦ Antihypertensive (/metabolite_ontology_terms/3449681)
`
`Physical Properties
`
`State
`
`Liquid
`
`http://www.hmdb.ca/metabolites/HMDB0014792
`
`7/25/2018
`
`IPR Page 2/5
`
`

`

`Human Metabolome Database: Showing metabocard for Latanoprost (HMDB0014792)
`
`Page 3 of 5
`
`Experimental Properties
`
`Predicted Properties
`
`Property
`
`Melting Point
`
`Boiling Point
`
`Water Solubility
`
`LogP
`
`Property
`
`Water Solubility
`
`logP
`
`logP
`
`logS
`
`pKa (Strongest Acidic)
`
`pKa (Strongest Basic)
`
`Physiological Charge
`
`Hydrogen Acceptor Count
`
`Hydrogen Donor Count
`
`Polar Surface Area
`
`Rotatable Bond Count
`
`Value
`
`Not Available
`
`Not Available
`
`0.013 g/L
`
`4.4
`
`Value
`
`0.013 g/L
`
`4.16
`
`3.98
`
`-4.5
`
`14.47
`
`-2.7
`
`0
`
`4
`
`3
`
`86.99 Ų
`
`14
`
`Reference
`
`Not Available
`
`Not Available
`
`Not Available
`
`Not Available
`
`Source
`
`ALOGPS (http://www.vcclab.org/lab/alogps/)
`
`ALOGPS (http://www.vcclab.org/lab/alogps/)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`predictors/#logp_logd)
`
`ALOGPS (http://www.vcclab.org/lab/alogps/)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-predictors/#pka)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`calculations/#h_bond)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`calculations/#h_bond)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`calculations/#topolgical_surface)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`calculations/#topology_analysis)
`
`Refractivity
`
`Polarizability
`
`Number of Rings
`
`Bioavailability
`
`Rule of Five
`
`Ghose Filter
`
`Veber's Rule
`
`MDDR-like Rule
`
`124.34 m³·mol⁻¹
`
`50.71 ų
`
`2
`
`1
`
`Yes
`
`Yes
`
`Yes
`
`Yes
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`calculations/#refractivity)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-
`modelling/#polarization)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/property-
`calculations/#topology_analysis)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-
`modelling/#polarization)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-
`modelling/#polarization)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-
`modelling/#polarization)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-
`modelling/#polarization)
`
`ChemAxon (http://www.chemaxon.com/products/calculator-plugins/molecular-
`modelling/#polarization)
`
`Spectra
`
`Spectra
`
`Spectrum
`Type
`
`Predicted
`GC-MS
`
`Description
`
`Predicted GC-MS Spectrum -
`GC-MS (Non-derivatized) -
`70eV, Positive
`(/spectra/c_ms/17619)
`
`Splash Key
`(http://splash.fiehnlab.ucdavis.edu/)
`
`splash10-00kf-5469500000-
`3070e3312e2f54422eeb
`
`Predicted
`GC-MS
`
`Predicted GC-MS Spectrum -
`GC-MS (3 TMS) - 70eV,
`Positive (/spectra/c_ms/40446)
`
`splash10-001l-7110196000-
`109246e3e73496dba6fd
`
`View in MoNA
`
`
`
`(http://mona.fiehnlab.ucdavis.edu/#/spectra/splash/splash10-00kf-5469500000-3070e3312e2f54422eeb)
`
`View in MoNA
`
`
`
`(http://mona.fiehnlab.ucdavis.edu/#/spectra/splash/splash10-001l-7110196000-109246e3e73496dba6fd)
`
`Biological Properties
`
`Cellular Locations
`
`Biospecimen Locations
`
`Tissue Locations
`
`Pathways
`
`Normal Concentrations
`
`• Extracellular
`• Membrane
`
`• Blood
`• Urine
`
`Not Available
`
`Not Available
`Name
`
`SMPDB/Pathwhiz
`
`KEGG
`
`http://www.hmdb.ca/metabolites/HMDB0014792
`
`7/25/2018
`
`IPR Page 3/5
`
`

`

`Human Metabolome Database: Showing metabocard for Latanoprost (HMDB0014792)
`
`Page 4 of 5
`
`Biospecimen Status
`
`Value
`
`Blood
`
`Urine
`
`Expected
`but not
`Quantified
`
`Expected
`but not
`Quantified
`
`Age
`
`Not Available
`
`Not
`Available
`
`Not Available
`
`Not
`Available
`
`Sex
`
`Condition Reference
`
`Details
`
`21059682
`
`
`
`(http://www.ncbi.nlm.nih.gov/pubmed/21059682)
`
`
`
`details (/concentrations/67281)
`
`21059682
`
`
`
`(http://www.ncbi.nlm.nih.gov/pubmed/21059682)
`
`
`
`details (/concentrations/67280)
`
`Taking
`drug
`identified
`by
`DrugBank
`entry
`DB00654
`
`Taking
`drug
`identified
`by
`DrugBank
`entry
`DB00654
`
`Abnormal Concentrations
`
`Not Available
`
`Associated Disorders and Diseases
`
`Disease References
`
`Associated OMIM IDs
`
`None
`
`None
`
`External Links
`
`DrugBank ID
`
`DB00654
`
`
`
`(http://www.drugbank.ca/drugs/DB00654)
`
`Phenol Explorer Compound ID Not Available
`
`FoodDB ID
`
`KNApSAcK ID
`
`Chemspider ID
`
`KEGG Compound ID
`
`BioCyc ID
`
`BiGG ID
`
`Wikipedia Link
`
`METLIN ID
`
`Not Available
`
`Not Available
`
`4470740
`
`
`
`(http://www.chemspider.com/Chemical-Structure.4470740.html)
`
`Not Available
`
`Not Available
`
`Not Available
`
`Latanoprost
`
`
`
`(http://en.wikipedia.org/wiki/Latanoprost)
`
`Not Available
`
`PubChem Compound
`
`5311221
`
`
`
`(http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=5311221)
`
`PDB ID
`
`ChEBI ID
`
`References
`
`Synthesis Reference
`
`Material Safety Data Sheet
`(MSDS)
`
`General References
`
`Enzymes
`
`Not Available
`
`6384
`
`
`
`(http://www.ebi.ac.uk/chebi/searchId.do?chebiId=6384)
`
`Not Available
`
`Not Available
`
`1. Hara T: [Increased iris pigmentation after use of latanoprost in Japanese brown eyes]. Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21.
`[PubMed:11406947
`(http://www.ncbi.nlm.nih.gov/pubmed/11406947)]
`
`(http://www.ncbi.nlm.nih.gov/pubmed/11413487)]
`2. Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000 Oct;1(1):31-9. [PubMed:11413487
`
`3. Watson AD: Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Lipidomics: a global approach to lipid analysis in biological systems. J Lipid Res.
`2006 Oct;47(10):2101-11. Epub 2006 Aug 10. [PubMed:16902246
`(http://www.ncbi.nlm.nih.gov/pubmed/16902246)]
`
`4. Sethi JK, Vidal-Puig AJ: Thematic review series: adipocyte biology. Adipose tissue function and plasticity orchestrate nutritional adaptation. J Lipid Res. 2007 Jun;48(6):1253-62. Epub 2007
`Mar 20. [PubMed:17374880
`(http://www.ncbi.nlm.nih.gov/pubmed/17374880)]
`
`5. Lingwood D, Simons K: Lipid rafts as a membrane-organizing principle. Science. 2010 Jan 1;327(5961):46-50. doi: 10.1126/science.1174621.
`[PubMed:20044567
`(http://www.ncbi.nlm.nih.gov/pubmed/20044567)]
`
`6. Gunstone, Frank D., John L. Harwood, and Albert J. Dijkstra (2007). The lipid handbook with CD-ROM. CRC Press.
`
`1. Prostaglandin F2-alpha receptor (/proteins/HMDBP01950)
`
`
`
`Enzyme Details (/proteins/HMDBP01950)
`
`General function:
`Specific function:
`
`Gene Name:
`Uniprot ID:
`Molecular weight:
`
`References
`
`Involved in G-protein coupled receptor protein signaling pathway
`Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis
`in the corpus luteum
`PTGFR
`P43088
`40054.1
`
`(http://www.uniprot.org/uniprot/P43088)
`
`
`
`1. Ota T, Aihara M, Narumiya S, Araie M: The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005 Nov;46(11):4159-63.
`[PubMed:16249494
`(http://www.ncbi.nlm.nih.gov/pubmed/16249494)]
`
`2. Nakajima T, Matsugi T, Goto W, Kageyama M, Mori N, Matsumura Y, Hara H: New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents. Biol Pharm Bull. 2003
`Dec;26(12):1691-5. [PubMed:14646172
`(http://www.ncbi.nlm.nih.gov/pubmed/14646172)]
`
`3. Takagi Y, Nakajima T, Shimazaki A, Kageyama M, Matsugi T, Matsumura Y, Gabelt BT, Kaufman PL, Hara H: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular
`hypotensive drug. Exp Eye Res. 2004 Apr;78(4):767-76. [PubMed:15037111
`(http://www.ncbi.nlm.nih.gov/pubmed/15037111)]
`
`4. Ocklind A: Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res. 1998 Aug;67(2):179-91.
`[PubMed:9733584
`(http://www.ncbi.nlm.nih.gov/pubmed/9733584)]
`
`5. Maxey KM, Johnson JL, LaBrecque J: The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol. 2002 Aug;47 Suppl 1:S34-40.
`[PubMed:12204699
`(http://www.ncbi.nlm.nih.gov/pubmed/12204699)]
`
`6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352
`
`(http://www.ncbi.nlm.nih.gov/pubmed/11752352)]
`
`
`
`Transporters
`
`1. Solute carrier organic anion transporter family member 2B1(/proteins/HMDBP02021)
`
`
`
`Enzyme Details (/proteins/HMDBP02021)
`
`General function:
`Specific function:
`Gene Name:
`Uniprot ID:
`
`Involved in transporter activity
`Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost
`SLCO2B1
`O94956
`
`
`(http://www.uniprot.org/uniprot/O94956)
`
`http://www.hmdb.ca/metabolites/HMDB0014792
`
`7/25/2018
`
`IPR Page 4/5
`
`

`

`Human Metabolome Database: Showing metabocard for Latanoprost (HMDB0014792)
`
`Page 5 of 5
`
`Molecular weight:
`
`76697.9
`
`References
`
`1. Kraft ME, Glaeser H, Mandery K, Konig J, Auge D, Fromm MF, Schlotzer-Schrehardt U, Welge-Lussen U, Kruse FE, Zolk O: The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the
`antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11. doi: 10.1167/iovs.09-4290. Epub 2009 Dec 17. [PubMed:20019365
`(http://www.ncbi.nlm.nih.gov/pubmed/20019365)]
`
`
`(http://www.cihr-irsc.gc.ca)
`
`(http://www.metabolomicscentre.ca)
`
`(http://www.aihealthsolutions.ca)
`
`(http://genomealberta.ca)
`
`(http://genomebc.ca)
`
`(http://genomecanada.ca)
`
`This project is supported by the Canadian Institutes of Health Research (http://www.cihr-irsc.gc.ca) (award #111062), Alberta Innovates - Health Solutions (http://www.aihealthsolutions.ca), and by The Metabolomics Innovation Centre
`(TMIC) (http://www.metabolomicscentre.ca/), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta (http://www.genomealberta.ca), Genome
`British Columbia (http://www.genomebc.ca/), and Genome Canada (http://www.genomecanada.ca), a not-for-profit organization that is leading Canada's national genomics strategy with $900 million in funding from the federal government.
`HMDB Version 4.0 — Contact Us (/w/contact)
`
`http://www.hmdb.ca/metabolites/HMDB0014792
`
`7/25/2018
`
`IPR Page 5/5
`
`